Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

被引：70
作者：
Pu, Dan [1 ]
Yin, Liyuan [1 ]
Huang, Lin [1 ]
Qin, Changlong [1 ]
Zhou, Yuwen [2 ]
Wu, Qiang [1 ]
Li, Yan [1 ]
Zhou, Qinghua [1 ]
Li, Lu [1 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Lung Canc Ctr, Lung Canc Ctr, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
cyclooxygenase-2; immunotherapy; cancer; combination therapy; celecoxib; CELL LUNG-CANCER; PHASE-II TRIAL; PD-L1; EXPRESSION; PROGNOSTIC VALUE; CELECOXIB; COX-2; BIOMARKER; BLOCKADE; DRIVEN;
D O I：
10.3389/fonc.2021.637504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E-2 (PGE2) that has been proved to promote the development, proliferation and metastasis of tumor cells. Recent studies further find the PGE2 in tumor microenvironment (TME) actively triggers tumor immune evasion via many ways, leading to poor response of immunotherapy. COX-2 inhibitor is suggested to restrain the immunosuppression of PGE2 and may enhance or reverse the response of immune checkpoint inhibitors (ICIs). This review provides insight into the mechanism of COX-2/PGE2 signal in immunosuppressive TME and summarizes the clinical application and trials in cancer treatment.
引用
收藏
页数：7
相关论文
共 54 条
[31]   Cyclooxygenase-2 in gastrointestinal malignancies [J].
Nagaraju, Ganji Purnachandra ;
El-Rayes, Bassel F. .
CANCER, 2019, 125 (08) :1221-1227
[32]  
Panadol, 2012, MIMS ANN REPORT CHIN, V15th
[33]   The blockade of immune checkpoints in cancer immunotherapy [J].
Pardoll, Drew M. .
NATURE REVIEWS CANCER, 2012, 12 (04) :252-264
[34]   Prostaglandin E2 Secreted by Thyroid Cancer Cells Contributes to Immune Escape Through the Suppression of Natural Killer (NK) Cell Cytotoxicity and NK Cell Differentiation [J].
Park, Arum ;
Lee, Yunhee ;
Kim, Mi Sun ;
Kang, Young Ju ;
Park, Young-Jun ;
Jung, Haiyoung ;
Kim, Tae-Don ;
Lee, Hee Gu ;
Choi, Inpyo ;
Yoon, Suk Ran .
FRONTIERS IN IMMUNOLOGY, 2018, 9
[35]   Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes [J].
Pedersen, Malin ;
Kuesters-Vandevelde, Heidi V. N. ;
Viros, Amaya ;
Groenen, Patricia J. T. A. ;
Sanchez-Laorden, Berta ;
Gilhuis, Jacobus H. ;
van Engen-van Grunsven, Ilse A. ;
Renier, Willy ;
Schieving, Jolanda ;
Niculescu-Duvaz, Ion ;
Springer, Caroline J. ;
Kuesters, Benno ;
Wesseling, Pieter ;
Blokx, Willeke A. M. ;
Marais, Richard .
CANCER DISCOVERY, 2013, 3 (04) :458-469
[36]   Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors [J].
Pitt, Jonathan M. ;
Vetizou, Marie ;
Daillere, Romain ;
Roberti, Maria Paula ;
Yamazaki, Takahiro ;
Routy, Bertrand ;
Lepage, Patricia ;
Boneca, Ivo Gomperts ;
Chamaillard, Mathias ;
Kroemer, Guido ;
Zitvogel, Laurence .
IMMUNITY, 2016, 44 (06) :1255-1269
[37]   Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs [J].
Porta, Chiara ;
Consonni, Francesca Maria ;
Morlacchi, Sara ;
Sangaletti, Sabina ;
Bleve, Augusto ;
Totaro, Maria Grazia ;
Larghi, Paola ;
Rimoldi, Monica ;
Tripodo, Claudio ;
Strauss, Laura ;
Banfi, Stefania ;
Storto, Mariangela ;
Pressiani, Tiziana ;
Rimassa, Lorenza ;
Tartari, Silvia ;
Ippolito, Alessandro ;
Doni, Andrea ;
Solda, Giulia ;
Duga, Stefano ;
Piccolo, Viviana ;
Ostuni, Renato ;
Natoli, Gioacchino ;
Bronte, Vincenzo ;
Balzac, Fiorella ;
Turco, Emilia ;
Hirsch, Emilio ;
Colombo, Mario P. ;
Sica, Antonio .
CANCER RESEARCH, 2020, 80 (13) :2874-2888
[38]   Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM( Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial [J].
Ruschitzka, Frank ;
Borer, Jeffrey S. ;
Krum, Henry ;
Flammer, Andreas J. ;
Yeomans, Neville D. ;
Libby, Peter ;
Luscher, Thomas F. ;
Solomon, Daniel H. ;
Husni, M. Elaine ;
Graham, David Y. ;
Davey, Deborah A. ;
Wisniewski, Lisa M. ;
Menon, Venu ;
Fayyad, Rana ;
Beckerman, Bruce ;
Iorga, Dinu ;
Lincoff, A. Michael ;
Nissen, Steven E. .
EUROPEAN HEART JOURNAL, 2017, 38 (44) :3282-3292
[39]   Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer [J].
Shimizu, Katsuhiko ;
Okita, Riki ;
Saisho, Shinsuke ;
Maeda, Ai ;
Nojima, Yuji ;
Nakata, Masao .
ANTICANCER RESEARCH, 2018, 38 (08) :4637-4644
[40]   Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma [J].
Shimizu, Katsuhiko ;
Okita, Riki ;
Saisho, Shinsuke ;
Maeda, Ai ;
Nojima, Yuji ;
Nakata, Masao .
CANCER MANAGEMENT AND RESEARCH, 2017, 9 :741-750
123456